Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.36 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.36 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29138749 | 0.84 | STING1 (0.31) | THRBKMT2AALDH1A1CYP1A2MEN1 | |
| SCHEMBL20805050 | 0.84 | CYP1A2 (0.42) | LMNATHRBKMT2AALDH1A1CYP1A2 | |
| SCHEMBL28812252 | 0.84 | NAAA (0.34) | THRBKMT2AALDH1A1CYP1A2MEN1 | |
| SCHEMBL14361939 | 0.84 | STING1 (0.31) | THRBKMT2AALDH1A1CYP1A2MEN1 | |
| SCHEMBL12227935 | 0.82 | ALDH1A1 (0.36) | LMNAALKBH5SUCNR1EGLN1THRB | |
| SCHEMBL19541803 | 0.81 | CA2 (0.39) | KMT2AMEN1HDAC3HDAC1 | |
| SCHEMBL17641641 | 0.81 | KDM4E (0.33) | LMNAALDH1A1CYP1A2BLMPMP22 | |
| SCHEMBL14474339 | 0.80 | LMNA (0.32) | LMNAALKBH5SUCNR1EGLN1THRB | |
| SCHEMBL10215089 | 0.80 | LMNA (0.40) | LMNAALKBH5SUCNR1EGLN1THRB | |
| SCHEMBL439245 | 0.79 | ALDH1A1 (0.39) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661892-A1 | TNF-ALPHA BINDING AGENTS AND METHODS OF USING THE SAME | Navigen, Inc. (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2024168055-A1 | TNF-ALPHA BINDING AGENTS AND METHODS OF USING THE SAME | NAVIGEN, INC. (US) | 2024-08-15 | — | — | WO | claimed |
| WO-2013000970-A1 | BIS TRIDENTATE W3O2 CLUSTERS FOR X-RAY IMAGING | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-03 | — | — | WO | claimed |
| EP-2540321-A1 | Bis Tridentate W3O2 Clusters for X-Ray imaging | Bayer Intellectual Property GmbH (DE) | 2013-01-02 | — | — | EP | claimed |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4661892-A1 | TNF-ALPHA BINDING AGENTS AND METHODS OF USING THE SAME | Navigen, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4598928-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4537854-A1 | COMPOUND FOR CONJUGATION, CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Formosa Laboratories, Inc. (TW) | 2025-04-16 | — | — | EP | disclosed |
| US-20250114473-A1 | COMPOUND FOR CONJUGATION, CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FORMOSA LABORATORIES, INC. (TW) | 2025-04-10 | — | — | US | disclosed |
| WO-2024168055-A1 | TNF-ALPHA BINDING AGENTS AND METHODS OF USING THE SAME | NAVIGEN, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-11993710-B2 | Composite solid state electrolyte and lithium ion battery containing the same | WILDCAT DISCOVERY TECHNOLOGIES, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024077006-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2009073809-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009043899-A1 | DRUG TRANSFER INTO LIVING CELLS | COVALYS BIOSCIENCES AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | BRACCO IMAGING S.P.A. (IT) | 2008-12-25 | — | — | US | disclosed |
| WO-2007135483-A2 | BIOMOLECULE INTERACTION USING ATOMIC FORCE MICROSCOPE | POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY (US) | 2007-11-29 | — | — | WO | disclosed |
| EP-1317422-A4 | SUBSTRATE WITH CONTROLLED AMINE DENSITY AND REGULAR SPACING AND METHOD FOR PREPARING THE SAME | POSCO (KR) | 2004-06-30 | — | — | EP | disclosed |
| US-20030199577-A1 | Substrate with controlled amine density and regular spacing and method for preparing the same | POSTECH FOUNDATION (KR) | 2003-10-23 | — | — | US | disclosed |
| EP-1317422-A1 | SUBSTRATE WITH CONTROLLED AMINE DENSITY AND REGULAR SPACING AND METHOD FOR PREPARING THE SAME | Posco (KR) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020469-A1 | SUBSTRATE WITH CONTROLLED AMINE DENSITY AND REGULAR SPACING AND METHOD FOR PREPARING THE SAME | POHANG IRON & STEEL CO., LTD. (KR) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | LMNA 3318/4885ALKBH5 4520/4885SUCNR1 255/4885 |
| US-20250114473-A1 | COMPOUND FOR CONJUGATION, CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ABCB1, UGT1A9, ABCG2 | LMNA 4171/4885ALKBH5 2224/4885SUCNR1 2988/4885 |
| US-20030199577-A1 | Substrate with controlled amine density and regular spacing and method for preparing the same | ADRA1B, ADRA1D, CYP4Z1 | LMNA 3528/4885ALKBH5 240/4885SUCNR1 1580/4885 |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | ITGA2B, ITGB2, ITGB1 | LMNA 2877/4885ALKBH5 4400/4885SUCNR1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.